May 31, 2016 7:00am EDT Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
May 26, 2016 8:30am EDT Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
May 19, 2016 6:00am EDT Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
May 9, 2016 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
May 2, 2016 7:05am EDT Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
Mar 29, 2016 7:00am EDT Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
Mar 9, 2016 7:00am EST Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
Mar 4, 2016 7:00am EST Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
